 This Fast Track status adds five more years of exclusivity for ridinazole.Speaking about Ridinilazole, Robert Duggan states, “Targeted antibiotics have the potential to improve the way infectious diseases are treated by targeting the infectious bacteria and minimising the damage of the healthy and protective microbiome.In C. difficile infection, the selective targeting of the infectious bacteria has significant potential to reduce recurrence and improve patient outcomes.”

Ridinilazole is manufactured by Summit Therapeutics.